INTRODUCTION: Lung cancer and chronic obstructive pulmonary disease (COPD) share environmental risk factors. COPD also increases the risk of lung cancer; however, the molecular mechanisms are unclear. METHODS: An epigenome-wide association study of lung tumors and cancer-free lung tissue (CFLT) pairs from non-small-cell lung cancer cases with (n = 18) or without (n = 17) COPD was conducted using the HumanMethylation450 beadchip (HM450K). COPD-associated methylation of top-ranked genes was confirmed in a larger sample set, independently validated, and their potential as sputum-based biomarkers was investigated. RESULTS: Methylation of CCDC37 and MAP1B was more prevalent in lung tumors from COPD than non-COPD cases [54 of 71 (76%) versus 20 of 46 (43%), p = 0.0013] and [48 of 71 (68%) versus 17 of 46 (37%), p = 0.0035], respectively, after adjustment for age, sex, smoking status, and tumor histology. HM450K probes across CCDC37 and MAP1B promoters showed higher methylation in tumors than CFLT with the highest methylation seen in tumors from COPD cases (p < 0.05). These results were independently validated using The Cancer Genome Atlas data. CCDC37 methylation was more prevalent in sputum from COPD than non-COPD smokers (p < 0.005) from two cohorts. CCDC37 and MAP1B expression was dramatically repressed in tumors and CFLT from COPD than non-COPD cases, p less than 0.02. CONCLUSIONS: The reduced expression of CCDC37 and MAP1B associated with COPD likely predisposes these genes to methylation that in turn, may contribute to lung cancer.
INTRODUCTION:Lung cancer and chronic obstructive pulmonary disease (COPD) share environmental risk factors. COPD also increases the risk of lung cancer; however, the molecular mechanisms are unclear. METHODS: An epigenome-wide association study of lung tumors and cancer-free lung tissue (CFLT) pairs from non-small-cell lung cancer cases with (n = 18) or without (n = 17) COPD was conducted using the HumanMethylation450 beadchip (HM450K). COPD-associated methylation of top-ranked genes was confirmed in a larger sample set, independently validated, and their potential as sputum-based biomarkers was investigated. RESULTS: Methylation of CCDC37 and MAP1B was more prevalent in lung tumors from COPD than non-COPD cases [54 of 71 (76%) versus 20 of 46 (43%), p = 0.0013] and [48 of 71 (68%) versus 17 of 46 (37%), p = 0.0035], respectively, after adjustment for age, sex, smoking status, and tumor histology. HM450K probes across CCDC37 and MAP1B promoters showed higher methylation in tumors than CFLT with the highest methylation seen in tumors from COPD cases (p < 0.05). These results were independently validated using The Cancer Genome Atlas data. CCDC37 methylation was more prevalent in sputum from COPD than non-COPD smokers (p < 0.005) from two cohorts. CCDC37 and MAP1B expression was dramatically repressed in tumors and CFLT from COPD than non-COPD cases, p less than 0.02. CONCLUSIONS: The reduced expression of CCDC37 and MAP1B associated with COPD likely predisposes these genes to methylation that in turn, may contribute to lung cancer.
Authors: Shuguang Leng; Yushi Liu; Cynthia L Thomas; W James Gauderman; Maria A Picchi; Shannon E Bruse; Xiequn Zhang; Kristina G Flores; David Van Den Berg; Christine A Stidley; Frank D Gilliland; Steven A Belinsky Journal: Am J Respir Crit Care Med Date: 2013-11-01 Impact factor: 21.405
Authors: Mathewos Tessema; Christin M Yingling; Yushi Liu; Carmen S Tellez; Leander Van Neste; Stephen S Baylin; Steven A Belinsky Journal: Carcinogenesis Date: 2014-01-07 Impact factor: 4.944
Authors: Ruben D Ramirez; Shelley Sheridan; Luc Girard; Mitsuo Sato; Young Kim; Jon Pollack; Michael Peyton; Ying Zou; Jonathan M Kurie; J Michael Dimaio; Sara Milchgrub; Alice L Smith; Rhonda F Souza; Laura Gilbey; Xi Zhang; Kenia Gandia; Melville B Vaughan; Woodring E Wright; Adi F Gazdar; Jerry W Shay; John D Minna Journal: Cancer Res Date: 2004-12-15 Impact factor: 12.701
Authors: Shuguang Leng; Yushi Liu; Joel L Weissfeld; Cynthia L Thomas; Younghun Han; Maria A Picchi; Christopher K Edlund; Randall P Willink; Autumn L Gaither Davis; Kieu C Do; Tomoko Nukui; Xiequn Zhang; Elizabeth A Burki; David Van Den Berg; Marjorie Romkes; W James Gauderman; Richard E Crowell; Yohannes Tesfaigzi; Christine A Stidley; Christopher I Amos; Jill M Siegfried; Frank D Gilliland; Steven A Belinsky Journal: J Natl Cancer Inst Date: 2015-02-23 Impact factor: 13.506
Authors: A Papi; G Casoni; G Caramori; I Guzzinati; P Boschetto; F Ravenna; N Calia; S Petruzzelli; L Corbetta; G Cavallesco; E Forini; M Saetta; A Ciaccia; L M Fabbri Journal: Thorax Date: 2004-08 Impact factor: 9.139
Authors: S A Belinsky; K J Nikula; W A Palmisano; R Michels; G Saccomanno; E Gabrielson; S B Baylin; J G Herman Journal: Proc Natl Acad Sci U S A Date: 1998-09-29 Impact factor: 11.205
Authors: Shannon Bruse; Hans Petersen; Joel Weissfeld; Maria Picchi; Randall Willink; Kieu Do; Jill Siegfried; Steven A Belinsky; Yohannes Tesfaigzi Journal: Respir Res Date: 2014-01-09
Authors: Mathewos Tessema; Christin M Yingling; Maria A Picchi; Guodong Wu; Tyrone Ryba; Yong Lin; Aaron O Bungum; Eric S Edell; Avrum Spira; Steven A Belinsky Journal: Cancer Lett Date: 2017-09-29 Impact factor: 8.679
Authors: Mathewos Tessema; Dereje D Tassew; Christin M Yingling; Kieu Do; Maria A Picchi; Guodong Wu; Hans Petersen; Scott Randell; Yong Lin; Steven A Belinsky; Yohannes Tesfaigzi Journal: Lung Cancer Date: 2020-05-25 Impact factor: 5.705
Authors: Shuguang Leng; Brenda Diergaarde; Maria A Picchi; David O Wilson; Frank D Gilliland; Jian-Min Yuan; Jill M Siegfried; Steven A Belinsky Journal: Am J Respir Crit Care Med Date: 2018-07-15 Impact factor: 30.528